Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

CIHR Institute of Aging’s scientific director announces new Canadian funding and discusses where the research is headed ...

Dementia diagnosis delays are widespread, averaging 3.5 years and stretching over 4 years for younger adults. Researchers ...

An NYPD officer, a security guard, and two women who worked in the building were killed. Here are the latest developments.

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

Ozzy Osbourne once discussed his health struggles and how he had endured a period of suffering in the lead-up to his death at ...

Getting older can be challenging, but with planning, building a support team, and taking advantage of free services, you can ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...